Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Immediate hypersensitivity
- Focus Therapeutic Use
- 15 Feb 2018 Status changed from recruiting to completed.
- 06 Feb 2017 Planned number of patients changed from 20 to 10.
- 22 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.